Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
2012; Massachusetts Medical Society; Volume: 366; Issue: 23 Linguagem: Inglês
10.1056/nejmoa1112433
ISSN1533-4406
AutoresMaria Tarcela Gler, Vija Skripconoka, Epifanio Sànchez-Garavito, Heping Xiao, José Luis Cabrera, Dante E. Vargas-Vasquez, Mengqiu Gao, Mohamed Awad, Seung-Kyu Park, Tae Sun Shim, Gee Young Suh, Manfred Danilovitš, Hideo Ogata, Anu Kurve, Joon Chang, Katsuhiro Suzuki, Thelma E. Tupasi, Won‐Jung Koh, Barbara Seaworth, Lawrence Geiter, Charles D. Wells,
Tópico(s)Pneumocystis jirovecii pneumonia detection and treatment
ResumoDelamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.
Referência(s)